{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:18:47Z","timestamp":1760059127126,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant Committee of the University of Debrecen, Scientific Publication Support Program","award":["PTP\/0289\/2024."],"award-info":[{"award-number":["PTP\/0289\/2024."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Interferon signature is one of the key pathogenic pathways in idiopathic inflammatory myopathies (IIMs), particularly in dermatomyositis (DM). The aim of this study was to analyze Siglec-1, an interferon-inducible receptor, on different monocyte subsets in IIM subtypes and investigate its association with disease activity measures. Siglec-1 expression was measured by 8-color flow cytometry in 62 IIM patients and 10 healthy controls (HC). Disease activity was assessed using the International Myositis Assessment and Clinical Studies (IMACS) core set measures. Active DM patients exhibited significantly higher Siglec-1 mean fluorescence intensity (MFI) compared to inactive subgroups and HCs in every monocyte subset. Intermediate monocytes displayed the highest Siglec-1 expression across all groups and the strongest associations between disease activity markers. Siglec-1 expression on monocyte subsets was strongly associated with global, extramuscular global, constitutional, cutaneous, muscular, and gastrointestinal activity measures, but not with pulmonary, skeletal, and cardiac activities in the DM population. The best indicator of DM global disease activity among the examined biomarkers was Siglec-1 MFI on intermediate monocytes. Siglec-1 on intermediate monocytes correlates strongly with organ-specific clinical and biochemical markers of disease activity; therefore, it is a candidate biomarker for monitoring IIM disease activity. Siglec-1 could be useful in patient selection for interferon-targeted treatments.<\/jats:p>","DOI":"10.3390\/ijms26104950","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:58:22Z","timestamp":1747821502000},"page":"4950","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disease Activity-Dependent Siglec-1 Expression on Monocyte Subsets of Patients with Idiopathic Inflammatory Myopathies"],"prefix":"10.3390","volume":"26","author":[{"given":"S\u00e1ndor","family":"Bar\u00e1th","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-3828","authenticated-orcid":false,"given":"Melinda","family":"Nagy-Vincze","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Kun","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorottya","family":"Szinay","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Zolt\u00e1n","family":"Griger","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor G\u00e1bor","family":"B\u00e9ldi","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-1703","authenticated-orcid":false,"given":"Katalin","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Sz\u00e1raz-Sz\u00e9les","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7364-9906","authenticated-orcid":false,"given":"Zsuzsanna","family":"Hevessy","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-7911","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Griger","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic Inflammatory Myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and Management of Adult Inflammatory Myopathies","volume":"17","author":"Milisenda","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-Mediated Necrotizing Myopathy: Clinical Features and Pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-Alpha\/Beta-Mediated Innate Immune Mechanisms in Dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00401-021-02365-5","article-title":"A Network of Core and Subtype-Specific Gene Expression Programs in Myositis","volume":"142","author":"Amici","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-Signature in Idiopathic Inflammatory Myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of Cutaneous Disease Activity with Type 1 Interferon Gene Signature and Interferon \u03b2 in Dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and Type I Interferon-Regulated Genes and Chemokines Mark Disease Activity in Dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients Is Associated with Disease Activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","article-title":"MxA Gene Expression in Juvenile Dermatomyositis Peripheral Blood Mononuclear Cells: Association with Muscle Involvement","volume":"120","author":"Abbott","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I Interferon-Inducible Gene Expression in Blood Is Present and Reflects Disease Activity in Dermatomyositis and Polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in Novel Biomarkers of Disease Activity in Juvenile and Adult Dermatomyositis Are Sensitive Biomarkers of Disease Course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and Type 1 Interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, Safety, and Target Engagement of Dazukibart, an IFN\u03b2 Specific Monoclonal Antibody, in Adults with Dermatomyositis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 Expression on Monocytes Is Associated with the Interferon Signature in Juvenile Dermatomyositis and Can Predict Treatment Response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/rheumatology\/keae630","article-title":"Type I Interferon Biomarker in Idiopathic Inflammatory Myopathies: Associations of Siglec-1 with Disease Activity and Treatment Response","volume":"64","author":"Kamperman","year":"2024","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e001934","DOI":"10.1136\/rmdopen-2021-001934","article-title":"SIGLEC1 Enables Straightforward Assessment of Type I Interferon Activity in Idiopathic Inflammatory Myopathies","volume":"8","author":"Graf","year":"2022","journal-title":"RMD Open"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Herzog, S., Fragkou, P.C., Arneth, B.M., Mkhlof, S., and Skevaki, C. (2022). Myeloid CD169\/Siglec1: An Immunoregulatory Biomarker in Viral Disease. Front. Med., 9.","DOI":"10.3389\/fmed.2022.979373"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kapellos, T.S., Bonaguro, L., Gem\u00fcnd, I., Reusch, N., Saglam, A., Hinkley, E.R., and Schultze, J.L. (2019). Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02035"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on Outcome Assessment in Myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103686","DOI":"10.1016\/j.autrev.2024.103686","article-title":"The Evaluation of Type I Interferon Score in Dermatomyositis, a Systematic Review and a Meta-Analysis","volume":"23","author":"Castellini","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision Medicine in Systemic Lupus Erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_25","first-page":"354","article-title":"Brepocitinib, a Potent and Selective TYK2\/JAK1 Inhibitor: Scientific and Clinical Rationale for Dermatomyositis","volume":"43","author":"Paik","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/bjd\/ljaf064","article-title":"Improvement in Dermatomyositis-Associated Muscle Disease with Anifrolumab","volume":"192","author":"Shayegan","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Helm, M.F., Maglakelidze, N., Shamloul, N., and Foulke, G. (2025). Successful Treatment of Refractory Cutaneous Dermatomyositis With Anifrolumab. Int. J. Dermatol.","DOI":"10.1111\/ijd.17675"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e11792","DOI":"10.1002\/acr2.11792","article-title":"Recalcitrant Dermatomyositis Treated With Anifrolumab","volume":"7","author":"Chaudhary","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ced\/llae476","article-title":"Anifrolumab Use in Refractory Dermatomyositis: A Case Report and Literature Review","volume":"50","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","article-title":"Gene Expression Profiling Reveals the Defining Features of the Classical, Intermediate, and Nonclassical Human Monocyte Subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lee, J., Tam, H., Adler, L., Ilstad-Minnihan, A., Macaubas, C., and Mellins, E.D. (2017). The MHC Class II Antigen Presentation Pathway in Human Monocytes Differs by Subset and Is Regulated by Cytokines. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183594"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.immuni.2010.08.012","article-title":"Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors","volume":"33","author":"Cros","year":"2010","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","article-title":"The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF","volume":"168","author":"Belge","year":"2002","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.exphem.2004.05.027","article-title":"Antitumor Response of CD14+\/CD16+ Monocyte Subpopulation","volume":"32","author":"Szaflarska","year":"2004","journal-title":"Exp. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1182\/blood-2011-01-326827","article-title":"SuperSAGE Evidence for CD14++CD16+ Monocytes as a Third Monocyte Subset","volume":"118","author":"Zawada","year":"2011","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jlb.67.5.699","article-title":"Differential Chemokine Receptor Expression and Function in Human Monocyte Subpopulations","volume":"67","author":"Weber","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.4049\/jimmunol.178.10.6581","article-title":"The CD16+ Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In Vivo","volume":"178","author":"Ellery","year":"2007","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/eji.1830230902","article-title":"The Novel Subset of CD14 +\/CD16 + Blood Monocytes Exhibits Features of Tissue Macrophages","volume":"23","author":"Fingerle","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1128\/IAI.66.6.2782-2790.1998","article-title":"Expanded CD14+ CD16+ Monocyte Subpopulation in Patients with Acute and Chronic Infections Undergoing Hemodialysis","volume":"66","author":"Nockher","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1762584","DOI":"10.1155\/2021\/1762584","article-title":"Participation of Monocyte Subpopulations in Progression of Experimental Endotoxemia (EE) and Systemic Inflammation","volume":"2021","author":"Radzyukevich","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yang, J., Zhang, L., Yu, C., Yang, X.-F., and Wang, H. (2014). Monocyte and Macrophage Differentiation: Circulation Inflammatory Monocyte as Biomarker for Inflammatory Diseases. Biomark. Res., 2.","DOI":"10.1186\/2050-7771-2-1"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed Preliminary Core Set Measures for Disease Outcome Assessment in Adult and Juvenile Idiopathic Inflammatory Myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the Reliability and Validity of Outcome Instruments for Cutaneous Dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic Repartition of Monocyte Subsets as a Diagnostic Signature of Chronic Myelomonocytic Leukemia","volume":"125","author":"Saada","year":"2015","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4950\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:36:37Z","timestamp":1760031397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26104950"],"URL":"https:\/\/doi.org\/10.3390\/ijms26104950","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}